Navigation Links
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Date:8/24/2009

CAMBRIDGE, Mass., Aug 24 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development.

Currently, Shire HGT has a unique and successful platform producing human cell derived enzyme replacement therapies (ERTs) for a wide range of rare human genetic disorders.

Sylvie Gregoire, President of Shire HGT, comments, "With this novel platform technology Shire has the potential to move into a wider range of genetic orphan diseases. We will look to develop treatments for people with a variety of rare life-altering and life-threatening conditions that to date, could not be effectively addressed by enzyme replacement therapy."

As part of the joint research project Santaris Pharma A/S will design, develop and deliver pre-clinical LNA oligonucleotides specific for the selected Shire targets, and Shire will have the right to further develop and commercialize these candidate compounds on a worldwide basis.

About Locked Nucleic Acid (LNA) Drug Platform

The Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetic chemical versions called LNAs of the normal nucleic acid building blocks of ribonucleic acids (RNA). These LNAs improve the drug-like qua
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering ... the Orange County, Texas area from future storm surge flooding, such as occurred in ... potential levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... ... Sherley says the company is making good progress in evaluating the full range ... adult tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and ...
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials can ... of liquid viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external ... What immediately catches the eye about Xsample 530 is its removable magazine, which is easily ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Patrick Dempsey is speaking out to help connect cancer ... Breakaway from Cancer® initiative. "Cancer ... diagnosed with ovarian cancer," explained Dempsey.  "I remember the feelings ... come to terms with the fear and shock of the ...
... Christine Pierre, president of RxTrials, Inc ., today named ... has been head of prime sites for Quintiles, will begin on ... "I have collaborated with Adam for 16 years and have ... what really stands out for me is his integrity. Yes, he brings ...
... Inc. (Nasdaq: NVAX ) has been named ... of Maryland (TCM), the largest technology trade group serving ... was recognized as the firm that best exemplifies the ... presence and leadership in Maryland. The criteria ...
Cached Biology Technology:Patrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources 2Patrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources 3RxTrials Announces Hiring Adam Chasse as VP of Business Development 2RxTrials Announces Hiring Adam Chasse as VP of Business Development 3Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland 2
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... , June 24, 2015 This report ... over the next six years. It contains an analysis ... industry, along with their impact from the short, medium, ... also discusses the industry, market, and technology trends that ... the need of concerned authorities to efficiently manage the ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Barr of the University,s Faculty of Biological Sciences are working ... bank of molecular signatures that will help identify the severity ... the team is barcoding different strains of influenza virus and ... the onset of asthma in young children. "Diseases such ...
... of biological inheritance is DNA replication a tightly coordinated ... thousands of different sites across the genome. If that copying ... cells with missing or extra genetic material, a hallmark of ... University of North Carolina School of Medicine scientists have ...
... ant species and a carnivorous plant, the ants contribute to ... provide significant amounts of nutrients derived from their wastes. This ... May 9 in the open access journal PLoS ... bicalcarata grows in the nutrient-poor peatswamp forests of Borneo ...
Cached Biology News:Virus 'barcodes' offer rapid detection of mutated strains 2DNA replication protein also has a role in mitosis, cancer 2
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: